Wikipedia -WSS

Wikipedia

author：explore 2025-09-27 16:11:34 - browse：58314

Maze Therapeutics CEO Jason Coloma Courtesy

After seeing its last deal go bust in the face of regulatory scrutiny, Maze Therapeutics has found another suitor for its experimental Pompe disease treatment.

Bay Area-based Maze and Shionogi said Friday that the Japanese pharma company had licensed the drug, called MZE001, with an upfront payment of $150 million. The global deal includes additional, undisclosed payments if the oral medication, which is in clinical testing, meets certain regulatory and commercial goals.

Last year, Sanofi, the French pharma giant, was set to pay $150 million in cash and stock to Maze before the transaction fell apart.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： What to expect at HLTH 2023, the health care industry conference

hotspot

WSS

Maui wildfire now ranks as the fifth

Timeline: How the deadly wildfires took over Maui day by day

Schizophrenia gene found to be linked to cells' energy dysfunction

Be careful with at

Dozens dead from Maui wildfires: What we know about the victims

Idaho college killings prosecutors challenge defense's grand jury claims

knowledge

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

In age of alternative facts, a scholarly course on calling out crap

FDA rejects Alnylam's heart disease treatment over insufficient data

Moonlake's readout produced a cash windfall. Risks remain

Illinois Supreme Court finds assault weapons ban constitutional

Apple is now the first public company to be valued at $3 trillion

Was Amgen transparent enough on FDA's concern on cancer drug?

Peter Hotez and the public health issue of online harassment

Treatments for cramps don't cut it. Why aren't there better options?

What does generative AI mean for health care? We asked experts

A virus, fished out of a lake, may have saved a man’s life

Wikipedia

Was Amgen transparent enough on FDA's concern on cancer drug?

Why Charlie Gard's case is so disturbing to Americans

Was Amgen transparent enough on FDA's concern on cancer drug?

BMS, looking to build heart drug business, turns to AI for diagnosis

Dozens dead from Maui wildfires: What we know about the victims

What to expect at HLTH 2023, the health care industry conference

hotspot

hotspot

focus

Wikipedia